While genomics may be inching toward the clinic, from a business perspective, the research end-market remains the prime target for most entrepreneurs in the space, writes Art Wuster at his Sequenomics blog.

Wuster looked at 72 firms listed on the technology company database Crunchbase, all of which received at least some third-party funding, and found that 38 were companies with customers in research laboratories or in other genomic firms.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Related Posts

This Week in Nucleic Acids Research: Researchers describe a new method to find large-scale structural variants in cancer genomes, a glimpse at an approach for profiling miRNAs in tumor samples from TCGA, and more.

Intellia Therapeutics has raised $70 million, becoming the latest firm leveraging the gene editing technology to haul in a gob of cash.

Now going beyond reporting fetal aneuploidies, NIPTs may be providing too much information that may be useless, some doctors and genetic counselor say.

A group of organizations in the UK say that there needs to be discussions about the use of technologies such as CRISPR/Cas-9 for human germline editing.